Compare Eli Lilly And Co (LLY) vs Western Alliance Bancorporation (WAL) Price & Performance

Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.

The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.

Western Alliance Bancorporation (WAL) trades at $74.27, down 0.11% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 8.52 and net income margin of 25.43%, while recent earnings beat expectations in two of the last three quarters. Analyst consensus remains strongly bullish with a $84.33 price target, supported by institutional buying activity and positive business developments including the launch of WA VenueX platform.

WAL presents a compelling value opportunity with attractive valuation metrics and solid profitability, though technical indicators suggest near-term weakness. Key risks include regulatory changes affecting banking thresholds and potential margin pressure from interest rate environment. The stock's 13.43% ROE and 79% analyst buy rating support long-term upside potential above current levels.